Botox Treatment for Overactive Bladder in Seniors: How Age Affects Long-Term Results

What is it about?

This study investigates the effect of age on the long-term efficacy of intradetrusor botulinum toxin (BoNT) treatment in elderly patients with refractory overactive bladder syndrome (OAB). Conducted in Nottingham, UK, and Melbourne, Australia, it analyzed data from 943 patients treated between 2005 and 2020, categorized into age groups from ≤40 to ≥70 years. Results showed varying efficacy rates across age groups and treatment cycles, with the ≥70 age group demonstrating reduced efficacy in Cycle 2. Neurological causes predicted increased efficacy in subsequent cycles. The study highlights that age, particularly ≥70 years, influences BoNT effectiveness, with men experiencing higher urinary retention rates than women.

Featured Image

Why is it important?

This research is significant because it explores the impact of age on the effectiveness of intradetrusor botulinum toxin (BoNT) therapy in elderly patients with refractory overactive bladder syndrome (OAB). Understanding how age affects treatment outcomes is crucial for optimizing therapeutic strategies and improving quality of life in this population. The findings contribute to the clinical knowledge base regarding age-specific responses to BoNT, which can inform personalized approaches to managing OAB in elderly patients. Furthermore, the study highlights potential age-related predictors of reduced treatment efficacy, guiding clinicians in selecting appropriate interventions for different age groups. Key Takeaways: 1. Age Impact: The study identifies age ≥ 70 as an independent predictor of reduced BoNT efficacy in Cycle 2, highlighting the importance of considering age-specific responses in treatment planning for elderly patients with refractory OAB. 2. Gender Differences: The research reveals higher rates of urinary retention in men compared to women following BoNT treatment, suggesting the need for gender-sensitive approaches in managing adverse effects associated with the therapy. 3. Neurogenic OAB: The study finds that neurogenic causes of OAB are predictors of increased efficacy in BoNT treatment, emphasizing the potential for tailored therapeutic strategies based on the underlying etiology of the bladder disorder.